Document is current
Any future updates will be listed below
-
Authors
Fneish, Firas https://orcid.org/0000-0001-8279-8463
Ellenberger, David https://orcid.org/0000-0002-2274-5025
Frahm, Niklas https://orcid.org/0000-0002-4655-774X
Stahmann, Alexander https://orcid.org/0000-0001-5308-105X
Fortwengel, Gerhard
Schaarschmidt, Frank https://orcid.org/0000-0002-6599-3803
-
Funding
Funding for this research was provided by:
Gottfried Wilhelm Leibniz Universität Hannover
- License Information
-
More Information
Article History
Received: 2 January 2023
Accepted: 8 June 2023
First Online: 14 July 2023
Declarations
:
: FF is an employee of Leibniz University Hannover and the German MS Registry. DE had no personal financial interests to disclose other than being an employee of the German MS Registry. NF is an employee of the MSFP. Moreover, he received travel funds for research meetings from Novartis. AS has no personal financial interests to disclose, other than being the leader of the German MS Registry, which receives (project) funding from a range of public and corporate sponsors, recently including G-BA, The German MS Trust, German MS Society, The German Retirement Insurance, Biogen, Celgene (Bristol Myers Squibb), Merck, Novartis, Roche, Sanofi and Viatris. GF has nothing to disclose. FS has nothing to disclose.
